Tuberculosis is one of the most topical health problems specialists face today as one-third of the worlds population is affected by this disease. For this reason, the case you investigate is crucial for the enhanced comprehending of the roots of the problem, causes for its development, and treatment. Your attempt to provide the most valuable information about the disease should be noted. The etiology, epidemiology, and pathophysiology of tuberculosis prove the dangerous character of the health issue and precondition the increased necessity to treat the patient you examine in the case.
The fact is that TB is curable and patients should be informed about it as their unwillingness to consult with a specialist could deteriorate the outcomes. Under these conditions, the choice of the appropriate treatment and timely interference become crucial for the overall success. To show a wide array of medicines that could be used to treat TB today, you enumerate such drugs as rifabutin (Mycobutin), amikacin (Amikin), and kanamycin (Kantrex), etc. However, the World Health Organization also recommends using new advanced drugs for multidrug (MDR) or extensively drug-resistant (XDR) tuberculosis to exclude failures and affect Mycobacterium Tuberculosis (Schito et al., 2015).
The recommended regimen includes at least four drugs to isolate the bacteria and improve the state of a patient (Cliff, Kaufmann, McShane, Helden, & OGarra, 2015). You suggest using the combination of rifater and ethambutol to attain enhanced outcomes. The proposed scheme could also be efficient and demonstrate significant improvement. However, in case the situation remains complex, the introduction of two additional drugs could be recommended. Altogether, you manage to prove the topical character of the issue and the need for effective approaches to assist patients in their recovery.
References
Cliff, J., Kaufmann, S., McShane, H., Helden, P., & OGarra, A. (2015). The human immune response to tuberculosis and its treatment: A view from the blood. Immunological Reviews, 264(1), 88-102. Web.
Schito, M., Migliori, G., Fletcher, H., McNerney, R., Centis, R., DAmbrosio, L.,… Zulma, A. (2015). Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines. Clinical Infectious Diseases, 61(3), 102-118. Web.